- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Reed Talks About How Savings Can Differ Between Patients, Health Plans
Julie M. Reed, the executive director of the Biosimilars Forum, discusses how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.
Julie M. Reed, the executive director of the Biosimilars Forum, discussed how biosimilar savings can differ between stakeholders and the importance of competition for creating those savings.
Transcript
How do the potential savings related to increased biosimilar utilization differ for health plans and patients?
That's a great question. I think it differs only in who the stakeholder is. The cost savings are there for everyone. Now, what really differs is the responsibility of the health plans. They can and should include all biosimilars on their formularies, and they should cover all biosimilars, and that gives patients and doctors access to all the biosimilars.
That's really key because what we know and our economic studies show is that the more biosimilars competing at the same time with the reference product, you're seeing the prices go down faster, you're seeing greater cost savings. If it's only 1 biosimilar vs all the biosimilars and having equal access and coverage, you're not seeing the robust competition that you could be having. That, in turn, [leads to] the price goes down, the co-pays go down, the prices for patients and everything else.
So, that's a key piece as far as the payers and their formularies, and Medicare, and the governments. They have a responsibility to really promote and increase the uptake to these lower-cost products.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
